Publication Type : Journal Article
Publisher : Curr Pharm Des
Source : Curr Pharm Des, Volume 25, Issue 33, p.3519-3535 (2019)
Url : https://pubmed.ncbi.nlm.nih.gov/31593530/
Keywords : Alzheimer disease, Cholinesterase Inhibitors, Donepezil, Drug Repositioning, galantamine, Humans, Rivastigmine, Tacrine
Campus : Kochi
School : School of Pharmacy
Department : Pharmaceutical Chemistry & Analysis
Year : 2019
Abstract : In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs which are under development and their respective mechanisms of actions.
Cite this Research Publication : M. Tanvir Kabir, Uddin, M. Sahab, Begum, M. Marium, Thangapandiyan, S., Rahman, M. Sohanur, Aleya, L., Bijo Mathew, Ahmed, M., Barreto, G. E., and Ashraf, G. Md, “Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.”, Curr Pharm Des, vol. 25, no. 33, pp. 3519-3535, 2019.